RT Journal Article
SR Electronic
T1 Perilipin-1 autoantibodies linked to idiopathic lipodystrophy in the setting of two distinct breaks in immune tolerance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.24.21263657
DO 10.1101/2021.09.24.21263657
A1 Mandel-Brehm, Caleigh
A1 Vazquez, Sara E.
A1 Liverman, Christopher
A1 Cheng, Mickie
A1 Quandt, Zoe
A1 Kung, Andrew F.
A1 Miao, Brenda
A1 Disse, Emmanuel
A1 Cugnet-Anceau, Christine
A1 Dalle, Stéphane
A1 Orlova, Elizaveta
A1 Frolova, Elena
A1 Oftedal, Bergithe E.
A1 Lionakis, Michail S.
A1 Husebye, Eystein S.
A1 DeRisi, Joseph L.
A1 Anderson, Mark S.
YR 2021
UL http://medrxiv.org/content/early/2021/09/28/2021.09.24.21263657.abstract
AB Background Acquired lipodystrophy is often characterized as an idiopathic subtype of lipodystrophy. Despite suspicion of an immune-mediated pathology, biomarkers such as autoantibodies are generally lacking.Methods Here, we used an unbiased proteome-wide screening approach to identify autoantibodies to the adipocyte specific lipid droplet protein Perilipin-1 in a murine model of Autoimmune Polyendocrine Syndrome 1 (APS1). We then tested for PLIN1 autoantibodies in human subjects with lipodystrophy with two independent severe breaks in immune tolerance (including APS1) along with controls using a specific Radioligand Binding Assay and indirect immunofluorescence on fat tissue.Results We identified autoantibodies to the lipid-droplet protein Perilipin-1 (PLIN1) in two human case reports including the first reported case of human APS1 with acquired lipodystrophy. Further, we extend PLIN1 autoantibodies to a second non-APS1 patient who acquired lipodystrophy as an immune-related adverse event following cancer immunotherapy.Conclusion These data suggest that PLIN1 autoantibodies may represent a unifying marker of autoimmune lipodystrophy.Competing Interest StatementSD received institutional research grants and travel cost covered by BMS and MSD.Funding StatementZ.Q. was supported by the American Diabetes Association grant 1- 19-PDF-131. JDL is funded by a grant from Chan Zuckerberg Biohub. JDL and CMB are funded by the National Institute of Mental Health (NIMH) of the NIH (award 1R01MH122471-01). CMB is funded by The Emiko Terasaki Foundation (Project 7027742 / Fund B73335) and by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (award 1K99NS117800-01). SEV is funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH (award 1F30DK123915-01). MSL is funded by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (ZIA AI001175). MA is funded by the National Institute of Allergy and Infectious Diseases (5P01AI118688-04), the National Institute of General Medical Sciences (5T32GM007618-42). EH is funded by Stiftelsen Kristian Gerhard Jebsen, The Novo Nordisk Foundation, The Research Council of Norway and the Regional Health Authorities of Western Norway.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Figure 2 involves our index APS1 patient with lipodystrophy (Case report 1) as well as APS1 patients without lipodystrophy and Healthy controls. Ethical approval for the study of the index APS1 patient with lipodystrophy was granted by the ethics committee at Endocrinology Research Center of Russia and all patients or their parents or guardians provided written informed consent. Ethical approval for the study of APS1 patients without lipodystrophy in Figure 2 was published previously (reference 11) and granted by the National Institute of Allergy and Infectious diseases (NIAID) Insitutional Review Board and patients provided written informed consent. Healthy control plamsa for Figure 2 was obtained from the New York Blood Center, where they were collected under informed consent, including usage for research and publication. Figure 3 involves our index cancer immunotherapy patient with lipodystrophy (Case report 2) as well as checkpoint immunotherapy patient (CP) controls. Ethical approval, signed and written informed consent for case report 2 in Figure 3 was granted by Hospices Civils de Lyon under the study Immune modulation Study in Patients with Metastatic Melanoma Treated with anti-PD1 Monoclonal Antibodies (PAIR)(Clinicaltrials.gov NCT02626065). Ethical approval for the study of CP controls for Figure 3 was provided by the Human Research Protection Program International Review Board and all participants gave written informed consent. Supplemental Figure S2 contains study of additional APS1 patients without lipodystrophy and Healthy Controls. Ethical approval for the study of all patients in Supplemental Figure 2 was granted by the Regional Ethical Committee of Western Norway (approval numbers 2009/2555 and 2018/1417), and all participants gave written informed consent for participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll additional data pertaining to PhIP-Seq, RLBA, and immunohistochemistry experiments not present in the paper is available upon request.